Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial - Wu, Y L; Zhou, C; Hu, C P (Lancet Oncol, 2014)
, et al.